We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of APC and Epo on the Inflammatory Response During Sepsis

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00229034
First Posted: September 29, 2005
Last Update Posted: August 25, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Lawson Health Research Institute
  Purpose
An observational study to determine the effect of APC and Epo in reducing the systemic inflammatory response during severe sepsis.

Condition
Sepsis Systemic Inflammation

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Effect of Activated Protein C and Erythropoietin on the Microvascular Inflammatory Response During Severe Sepsis.

Resource links provided by NLM:


Further study details as provided by Lawson Health Research Institute:

Enrollment: 40
Actual Study Start Date: September 2005
Study Completion Date: September 2011
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Detailed Description:
An observational study to determine the effect of APC and Epo in reducing the systemic inflammatory response during severe sepsis. Patients already prescribed either drug will be enrolled. The microcirculation of the sublingual vascular bed will be observed with a microscope to detect the alterations in the inflammatory response.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients in the ICU in severe septic shock receiving either APC and/or Epo
Criteria

Inclusion Criteria:

  • patients in the ICU in severe septic shock undergoing APC and/or Epo treatment

Exclusion Criteria:

  • any severe comorbid conditions
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00229034


Locations
Canada, Ontario
Lawson Health Research Institute
London, Ontario, Canada, N6A 4G5
Sponsors and Collaborators
Lawson Health Research Institute
Investigators
Principal Investigator: Amit Badhwar, PhD Scientist
Study Director: Neil Parry, MD Surgeon
  More Information

Responsible Party: Lawson Health Research Institute
ClinicalTrials.gov Identifier: NCT00229034     History of Changes
Other Study ID Numbers: R-05-382
11652E
First Submitted: September 27, 2005
First Posted: September 29, 2005
Last Update Posted: August 25, 2017
Last Verified: August 2017

Keywords provided by Lawson Health Research Institute:
Systemic Inflammation
Microvascular Perfusion
Septic Shock

Additional relevant MeSH terms:
Inflammation
Sepsis
Toxemia
Pathologic Processes
Infection
Systemic Inflammatory Response Syndrome